New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?

•Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement s...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2024-08, Vol.29 (8), p.104072, Article 104072
Main Authors: Sahebkar, Amirhossein, Gadde, Kishore M., Kroh, Matthew, Eid, Ali H., Jamialahmadi, Tannaz
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c241t-423a62ae823f391c10d90546eaed515d0d38df7622d2ad9672ee2f51e132e9b33
container_end_page
container_issue 8
container_start_page 104072
container_title Drug discovery today
container_volume 29
creator Sahebkar, Amirhossein
Gadde, Kishore M.
Kroh, Matthew
Eid, Ali H.
Jamialahmadi, Tannaz
description •Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement surgical procedures and improve weight loss.•Long-term safety and efficacy data of GLP-1 RAs in reducing cardiovascular outcomes are awaited.
doi_str_mv 10.1016/j.drudis.2024.104072
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3073653026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644624001971</els_id><sourcerecordid>3073653026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-423a62ae823f391c10d90546eaed515d0d38df7622d2ad9672ee2f51e132e9b33</originalsourceid><addsrcrecordid>eNp9kE1v3CAQhlGVqPlo_0FV-ZiLNzBgbPfQKFqlSaR8SW3PCMO4YbU2G8CJ9t-XrdMcc-KFeYbRPIR8YXTBKJOnq4UNk3VxARREfhK0hg_kkDV1U1YNh72cedWWUgh5QI5iXFHKoK3kR3LAm1ZA5g-JvcOX4hJHDDo5PxbnY3LlfYfRpW3x8KjDoI1Pj7m82X4rln7Y6HHH-fDvgsmlHJMvbjHpzq-dKTodnE4hp59T-INhe_aJ7Pd6HfHz63lMfv-4-LW8Km_uL6-X5zelAcFSKYBrCRob4D1vmWHUtrQSEjXailWWWt7YvpYAFrRtZQ2I0FcMGQdsO86Pycn87yb4pwljUoOLBtdrPaKfouK05rLiFGRGxYya4GMM2KtNcIMOW8Wo2vlVKzX7VTu_avab276-Tpi6Ae1b03-hGfg-A5j3fHYYVDQOR4PWBTRJWe_en_AX1pSOWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3073653026</pqid></control><display><type>article</type><title>New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?</title><source>ScienceDirect Journals</source><creator>Sahebkar, Amirhossein ; Gadde, Kishore M. ; Kroh, Matthew ; Eid, Ali H. ; Jamialahmadi, Tannaz</creator><creatorcontrib>Sahebkar, Amirhossein ; Gadde, Kishore M. ; Kroh, Matthew ; Eid, Ali H. ; Jamialahmadi, Tannaz</creatorcontrib><description>•Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement surgical procedures and improve weight loss.•Long-term safety and efficacy data of GLP-1 RAs in reducing cardiovascular outcomes are awaited.</description><identifier>ISSN: 1359-6446</identifier><identifier>ISSN: 1878-5832</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2024.104072</identifier><identifier>PMID: 38942072</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Drug discovery today, 2024-08, Vol.29 (8), p.104072, Article 104072</ispartof><rights>2024 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-423a62ae823f391c10d90546eaed515d0d38df7622d2ad9672ee2f51e132e9b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38942072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><creatorcontrib>Gadde, Kishore M.</creatorcontrib><creatorcontrib>Kroh, Matthew</creatorcontrib><creatorcontrib>Eid, Ali H.</creatorcontrib><creatorcontrib>Jamialahmadi, Tannaz</creatorcontrib><title>New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement surgical procedures and improve weight loss.•Long-term safety and efficacy data of GLP-1 RAs in reducing cardiovascular outcomes are awaited.</description><issn>1359-6446</issn><issn>1878-5832</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v3CAQhlGVqPlo_0FV-ZiLNzBgbPfQKFqlSaR8SW3PCMO4YbU2G8CJ9t-XrdMcc-KFeYbRPIR8YXTBKJOnq4UNk3VxARREfhK0hg_kkDV1U1YNh72cedWWUgh5QI5iXFHKoK3kR3LAm1ZA5g-JvcOX4hJHDDo5PxbnY3LlfYfRpW3x8KjDoI1Pj7m82X4rln7Y6HHH-fDvgsmlHJMvbjHpzq-dKTodnE4hp59T-INhe_aJ7Pd6HfHz63lMfv-4-LW8Km_uL6-X5zelAcFSKYBrCRob4D1vmWHUtrQSEjXailWWWt7YvpYAFrRtZQ2I0FcMGQdsO86Pycn87yb4pwljUoOLBtdrPaKfouK05rLiFGRGxYya4GMM2KtNcIMOW8Wo2vlVKzX7VTu_avab276-Tpi6Ae1b03-hGfg-A5j3fHYYVDQOR4PWBTRJWe_en_AX1pSOWg</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Sahebkar, Amirhossein</creator><creator>Gadde, Kishore M.</creator><creator>Kroh, Matthew</creator><creator>Eid, Ali H.</creator><creator>Jamialahmadi, Tannaz</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240801</creationdate><title>New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?</title><author>Sahebkar, Amirhossein ; Gadde, Kishore M. ; Kroh, Matthew ; Eid, Ali H. ; Jamialahmadi, Tannaz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-423a62ae823f391c10d90546eaed515d0d38df7622d2ad9672ee2f51e132e9b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><creatorcontrib>Gadde, Kishore M.</creatorcontrib><creatorcontrib>Kroh, Matthew</creatorcontrib><creatorcontrib>Eid, Ali H.</creatorcontrib><creatorcontrib>Jamialahmadi, Tannaz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahebkar, Amirhossein</au><au>Gadde, Kishore M.</au><au>Kroh, Matthew</au><au>Eid, Ali H.</au><au>Jamialahmadi, Tannaz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>29</volume><issue>8</issue><spage>104072</spage><pages>104072-</pages><artnum>104072</artnum><issn>1359-6446</issn><issn>1878-5832</issn><eissn>1878-5832</eissn><abstract>•Bariatric surgery (BS) remains the most effective and durable treatment for severe obesity,•GLP-1 RAs have shown promise in patients with inadequate weight loss or recurrence after BS.•Despite robust weight reduction in clinical trials, GLP-RAs are unlikely to replace BS.•GLP-1 RAs may complement surgical procedures and improve weight loss.•Long-term safety and efficacy data of GLP-1 RAs in reducing cardiovascular outcomes are awaited.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38942072</pmid><doi>10.1016/j.drudis.2024.104072</doi></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 2024-08, Vol.29 (8), p.104072, Article 104072
issn 1359-6446
1878-5832
1878-5832
language eng
recordid cdi_proquest_miscellaneous_3073653026
source ScienceDirect Journals
title New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T09%3A20%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20Generation%20Anti-Obesity%20Pharmacotherapy:%20Companion%20or%20Competitor%20to%20Metabolic%20bariatric%20Surgery?&rft.jtitle=Drug%20discovery%20today&rft.au=Sahebkar,%20Amirhossein&rft.date=2024-08-01&rft.volume=29&rft.issue=8&rft.spage=104072&rft.pages=104072-&rft.artnum=104072&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2024.104072&rft_dat=%3Cproquest_cross%3E3073653026%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c241t-423a62ae823f391c10d90546eaed515d0d38df7622d2ad9672ee2f51e132e9b33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3073653026&rft_id=info:pmid/38942072&rfr_iscdi=true